|
FDA Calls for Six Months of Stability Testing Data for ANDA Filers
Generic-drug makers filing ANDAs and drug master files should provide six months of stability testing data, including accelerated and long-term conditions, and data from three pilot scale batches, or two pilot batches and one small scale batch, the FDA’s Office of Generic Drugs (OGD) says in new draft guidance on stability testing.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives